![](/images/graphics-bg.png)
Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
Joint Authors
Qian, Zhengzi
Song, Zheng
Zhang, Huilai
Wang, Xianhuo
Zhao, Jing
Wang, Huaqing
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-03-19
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
T-cell lymphoma (TCL) is resistant to conventional chemotherapy.
We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL.
From 2002 to 2012, 69 patients with refractory or relapsed TCL received GND treatment in our hospital.
The treatment protocol comprised gemcitabine (800 mg/m2, group 1; 1000 mg/m2, group 2) on days 1 and 8, navelbine (25 mg/m2) on day 1, and doxorubicin (20 mg/m2) on day 1, repeated every 3 weeks.
The overall response rate (ORR) was 65.2%.
The median overall survival (OS) was 36 months.
The 5-year estimated OS rate was 32.4%.
The GND regimen was well tolerated.
Subgroup analysis demonstrated that the ORR and CR for group 1 were similar.
A longer median OS was observed for group 1.
Significant difference in grades 3-4 toxicities was observed between groups 1 and 2 (P=0.035).
Our study indicated that gemcitabine (800 mg/m2) on days 1 and 8 every 21 days was favorable for pretreated TCL patients.
American Psychological Association (APA)
Qian, Zhengzi& Song, Zheng& Zhang, Huilai& Wang, Xianhuo& Zhao, Jing& Wang, Huaqing. 2015. Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. BioMed Research International،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1056101
Modern Language Association (MLA)
Qian, Zhengzi…[et al.]. Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. BioMed Research International No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1056101
American Medical Association (AMA)
Qian, Zhengzi& Song, Zheng& Zhang, Huilai& Wang, Xianhuo& Zhao, Jing& Wang, Huaqing. Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1056101
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1056101